journal
MENU ▼
Read by QxMD icon Read
search

JAMA Oncology

journal
https://www.readbyqxmd.com/read/28097337/cancer-related-depression
#1
Rachel Roos Pokorney, Gleneara E Bates
No abstract text is available yet for this article.
January 12, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28097325/imaging-locally-advanced-recurrent-and-metastatic-prostate-cancer-a-review
#2
Maria L Lindenberg, Baris Turkbey, Esther Mena, Peter L Choyke
Importance: Prostate cancer is the second leading cause of cancer deaths in US men. The course of prostate cancer is highly variable, and timely and accurate detection of clinically significant cancer is critical in positively affecting outcomes. Observations: Molecular imaging methods and magnetic resonance imaging (MRI) are the most promising new developments for prostate tumor visualization. While the benefits of MRI are many, positron emission tomography (PET) radiotracers are still available only as research tools...
January 12, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28097324/molecular-based-recursive-partitioning-analysis-model-for-glioblastoma-in-the-temozolomide-era-a-correlative-analysis-based-on-nrg-oncology-rtog-0525
#3
Erica Hlavin Bell, Stephanie L Pugh, Joseph P McElroy, Mark R Gilbert, Minesh Mehta, Alexander C Klimowicz, Anthony Magliocco, Markus Bredel, Pierre Robe, Anca-L Grosu, Roger Stupp, Walter Curran, Aline P Becker, Andrea L Salavaggione, Jill S Barnholtz-Sloan, Kenneth Aldape, Deborah T Blumenthal, Paul D Brown, Jon Glass, Luis Souhami, R Jeffrey Lee, David Brachman, John Flickinger, Minhee Won, Arnab Chakravarti
Importance: There is a need for a more refined, molecularly based classification model for glioblastoma (GBM) in the temozolomide era. Objective: To refine the existing clinically based recursive partitioning analysis (RPA) model by incorporating molecular variables. Design, Setting, and Participants: NRG Oncology RTOG 0525 specimens (n = 452) were analyzed for protein biomarkers representing key pathways in GBM by a quantitative molecular microscopy-based approach with semiquantitative immunohistochemical validation...
January 12, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28097319/escalation-of-commitment-in-treatment-decisions-near-the-end-of-life
#4
Laurent Knoops, Philippe Bastin
No abstract text is available yet for this article.
January 12, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28097317/surrogate-end-points-for-all-cause-mortality-in-men-with-localized-unfavorable-risk-prostate-cancer-treated-with-radiation-therapy-vs-radiation-therapy-plus-androgen-deprivation-therapy-a-secondary-analysis-of-a-randomized-clinical-trial
#5
Trevor J Royce, Ming-Hui Chen, Jing Wu, Marian Loffredo, Andrew A Renshaw, Philip W Kantoff, Anthony V D'Amico
Importance: Several surrogates for prostate cancer-specific mortality satisfying the Prentice criteria exist, but whether these are surrogates for all-cause mortality, and how their performance compares, is unknown. Objective: To ascertain and compare the performance of 4 candidate surrogates (prostate-specific antigen [PSA] failure, PSA nadir >0.5 ng/mL, PSA doubling time <9 months, and interval to PSA failure <30 months) for all-cause mortality using the proportion of treatment-effect metric...
January 12, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28097315/the-significance-of-invasive-breast-cancer-associated-with-ductal-carcinoma-in-situ-dcis-compared-with-cancer-without-associated-dcis
#6
Steven Sorscher
No abstract text is available yet for this article.
January 12, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28056151/the-changing-role-of-whole-brain-radiotherapy-demise-or-time-for-selective-usage
#7
Minesh P Mehta, Hidefumi Aoyama, Vinai Gondi
No abstract text is available yet for this article.
January 5, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28056133/supplement-2-added
#8
(no author information available yet)
No abstract text is available yet for this article.
January 5, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28056130/bringing-adjuvant-chemotherapy-for-resected-non-small-cell-lung-cancer-into-real-world-practice-better-late-than-never
#9
Howard Jack West
No abstract text is available yet for this article.
January 5, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28056128/the-diminishing-role-of-whole-brain-radiation-therapy-in-the-treatment-of-brain-metastases
#10
Jing Li, Paul D Brown
No abstract text is available yet for this article.
January 5, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28056122/a-silver-lining
#11
Diya Kapila
No abstract text is available yet for this article.
January 5, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28056116/comparison-of-survival-outcomes-among-human-papillomavirus-negative-ct1-2-n1-2b-patients-with-oropharyngeal-squamous-cell-cancer-treated-with-upfront-surgery-vs-definitive-chemoradiation-therapy-an-observational-study
#12
Jacqueline R Kelly, Henry S Park, Yi An, Joseph N Contessa, Wendell G Yarbrough, Barbara A Burtness, Roy Decker, Zain Husain
Importance: Human papillomavirus (HPV)-negative oropharyngeal squamous cell carcinoma (OPSCC) has shown resistance to conventional concurrent chemoradiation (CRT) therapy and carries a relatively poor prognosis in comparison with HPV-positive disease, with decreased locoregional control and overall survival (OS). In the present analysis, we examine whether upfront surgical resection improves overall survival in a large national sample. Objective: To compare survival outcomes among patients with newly diagnosed cT1-2 N1-2b HPV-negative OPSCC when treated with primary surgical resection vs CRT...
January 5, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28056114/diagnosis-and-management-of-waldenstr%C3%A3-m-macroglobulinemia-mayo-stratification-of-macroglobulinemia-and-risk-adapted-therapy-msmart-guidelines-2016
#13
Prashant Kapoor, Stephen M Ansell, Rafael Fonseca, Asher Chanan-Khan, Robert A Kyle, Shaji K Kumar, Joseph R Mikhael, Thomas E Witzig, Michelle Mauermann, Angela Dispenzieri, Sikander Ailawadhi, A Keith Stewart, Martha Q Lacy, Carrie A Thompson, Francis K Buadi, David Dingli, William G Morice, Ronald S Go, Dragan Jevremovic, Taimur Sher, Rebecca L King, Esteban Braggio, Ann Novak, Vivek Roy, Rhett P Ketterling, Patricia T Greipp, Martha Grogan, Ivana N Micallef, P Leif Bergsagel, Joseph P Colgan, Nelson Leung, Wilson I Gonsalves, Yi Lin, David J Inwards, Suzanne R Hayman, Grzegorz S Nowakowski, Patrick B Johnston, Steven J Russell, Svetomir N Markovic, Steven R Zeldenrust, Yi L Hwa, John A Lust, Luis F Porrata, Thomas M Habermann, S Vincent Rajkumar, Morie A Gertz, Craig B Reeder
Importance: Waldenström macroglobulinemia (WM), an IgM-associated lymphoplasmacytic lymphoma, has witnessed several practice-altering advances in recent years. With availability of a wider array of therapies, the management strategies have become increasingly complex. Our multidisciplinary team appraised studies published or presented up to December 2015 to provide consensus recommendations for a risk-adapted approach to WM, using a grading system. Observations: Waldenström macroglobulinemia remains a rare, incurable cancer, with a heterogeneous disease course...
January 5, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28056112/association-of-delayed-adjuvant-chemotherapy-with-survival-after-lung-cancer-surgery
#14
Michelle C Salazar, Joshua E Rosen, Zuoheng Wang, Brian N Arnold, Daniel C Thomas, Roy S Herbst, Anthony W Kim, Frank C Detterbeck, Justin D Blasberg, Daniel J Boffa
Importance: Adjuvant chemotherapy offers a survival benefit to a number of staging scenarios in non-small-cell lung cancer. Variable recovery from lung cancer surgery may delay a patient's ability to tolerate adjuvant chemotherapy, yet the urgency of chemotherapy initiation is unclear. Objective: To assess differences in survival according to the time interval between non-small-cell lung cancer resection and the initiation of postoperative chemotherapy to determine the association between adjuvant treatment timing and efficacy...
January 5, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28033451/making-molecular-imaging-a-clinical-tool-for-precision-oncology-a-review
#15
David A Mankoff, Michael D Farwell, Amy S Clark, Daniel A Pryma
Importance: Individualized cancer treatment, tailored to a particular patient and the tumor's biological features (precision oncology), requires a detailed knowledge of tumor biology. Biological characterization is typically performed on biopsy material, but this approach can present challenges for widespread and/or heterogeneous disease and for performing serial assays to infer changes in response to therapy. Molecular imaging is a complementary approach that provides noninvasive and quantitative measures of the in vivo biology of the full disease burden and is well suited to serial assay...
December 29, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/28033449/processing-death
#16
Jessica W Tsai
No abstract text is available yet for this article.
December 29, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/28033448/second-opinions-from-medical-oncologists-for-early-stage-breast-cancer-prevalence-correlates-and-consequences
#17
Allison W Kurian, Christopher R Friese, Irina Bondarenko, Reshma Jagsi, Yun Li, Ann S Hamilton, Kevin C Ward, Steven J Katz
Importance: Advances in the evaluation and treatment of breast cancer have made the clinical decision-making context much more complex. A second opinion from a medical oncologist may facilitate decision making for women with breast cancer, yet little is known about second opinion use. Objective: To investigate the patterns and correlates of second opinion use and the effect on chemotherapy decisions. Design, Setting, and Participants: A total of 1901 women newly diagnosed with stages 0 to II breast cancer between July 2013 and September 2014 (response rate, 71...
December 29, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/28033447/assessment-of-overall-survival-quality-of-life-and-safety-benefits-associated-with-new-cancer-medicines
#18
Sebastian Salas-Vega, Othon Iliopoulos, Elias Mossialos
Importance: There is a dearth of evidence examining the impact of newly licensed cancer medicines on therapy. This information could otherwise support clinical practice, and promote value-based decision-making in the cancer drug market. Objective: To evaluate the comparative therapeutic value of all new cancer medicines approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) between 2003 and 2013. Design, Setting, and Participants: We used a narrative synthesis approach to systematically synthesize and analyze English, French, and Australian health technology assessments (HTAs) of all new cancer medicines licensed in the United States and Europe between 2003 and 2013...
December 29, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/28033446/increase-in-prostate-cancer-distant-metastases-at-diagnosis-in-the-united-states
#19
Jim C Hu, Paul Nguyen, Jialin Mao, Joshua Halpern, Jonathan Shoag, Jason D Wright, Art Sedrakyan
No abstract text is available yet for this article.
December 29, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/28033443/association-between-loss-of-function-mutations-within-the-fancm-gene-and-early-onset-familial-breast-cancer
#20
Guido Neidhardt, Jan Hauke, Juliane Ramser, Eva Groß, Andrea Gehrig, Clemens R Müller, Anne-Karin Kahlert, Karl Hackmann, Ellen Honisch, Dieter Niederacher, Stefanie Heilmann-Heimbach, André Franke, Wolfgang Lieb, Holger Thiele, Janine Altmüller, Peter Nürnberg, Kristina Klaschik, Corinna Ernst, Nina Ditsch, Frank Jessen, Alfredo Ramirez, Barbara Wappenschmidt, Christoph Engel, Kerstin Rhiem, Alfons Meindl, Rita K Schmutzler, Eric Hahnen
Importance: Germline mutations in established moderately or highly penetrant risk genes for breast cancer (BC) and/or ovarian cancer (OC), including BRCA1 and BRCA2, explain fewer than half of all familial BC and/or OC cases. Based on the genotyping of 2 loss-of-function (LoF) variants c.5101C>T (p.GIn1701Ter [rs147021911]) and c.5791C>T (p.Arg1931Ter [rs144567652]), the FANCM gene has been suggested as a novel BC predisposition gene, while the analysis of the entire coding region of the FANCM gene in familial index cases and geographically matched controls is pending...
December 29, 2016: JAMA Oncology
journal
journal
50067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"